Navigation Links
Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
Date:10/11/2007

MALVERN, Pa., Oct. 11 /PRNewswire/ -- Solstice Neurosciences, Inc. ("Solstice") announced the appointment of Dennis L. Smith to its Board of Directors. Mr. Smith will serve as Executive Chairman replacing James Thomas, who remains on the Board having served as Chairman since Solstice was founded in July 2004.

Mr. Smith brings unique specialty pharmaceutical industry experience and expertise to Solstice that will be invaluable in providing guidance and leadership for growth and maximizing stockholder value. Mr. Smith will work with the Board and Solstice management to review current operations and develop strategic options.

Mr. Smith has worked in the pharmaceutical industry since 1973, and most recently served as President and Chief Executive Officer of INO Therapeutics LLC., a specialty pharmaceutical company with strengths in development, marketing, and sales of critical care drugs and drug/device combinations, and focused on making innovative therapies available to healthcare professionals and patients. Prior to INO, Mr. Smith spent 15 years with DuPont Pharmaceutical Company, where he served as President of U.S. Operations, Executive Vice President of Global Health Systems, Executive Vice President in Europe, and Vice President and General Manager in Canada, among numerous other positions at DuPont Pharmaceuticals and DuPont Merck. Mr. Smith was also employed at Baxter International and Sandoz Pharmaceuticals (now Novartis). Mr. Smith is a graduate of Michigan State University and the Lake Forest Graduate School of Business.

"We are extremely pleased to have Dennis join the Board of Directors of Solstice," said Shawn Patrick O'Brien, President and Chief Executive Officer. "His wide-ranging experience in the biopharmaceutical industry will undoubtedly prove to be extremely valuable as Solstice continues to evolve and broaden our product portfolio globally," Mr. O'Brien said.

"I am excited to be joining the Board and eager to work with Shawn and the Solstice team as well as the Board members to better understand this dynamic and growing business and help lead the future direction. I also look forward to interacting with employees and the customers who treat the patients we ultimately serve," said Mr. Smith.

About Solstice Neurosciences, Inc.

Founded in 2004, Solstice Neurosciences, Inc. is a biopharmaceutical company focused on the development, manufacturing, sales and marketing of specialty products. Solstice's first product, MYOBLOC(R) (Botulinum Toxin Type B) Injectable Solution, represents the only botulinum toxin type B currently available to physicians and patients. MYOBLOC is sold in the United States and approved in Canada. It is also distributed and sold in the EU as NeuroBloc. MYOBLOC is indicated for the treatment of patients with cervical dystonia (CD) to reduce the severity of abnormal head position and pain associated with CD. For more information about Solstice Neurosciences, Inc., visit http://www.solsticeneuro.com.

Myobloc(R) and NeuroBloc(R) are registered trademarks of Solstice Neurosciences, Inc.


'/>"/>
SOURCE Solstice Neurosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Local meteorology company accurately predicts Hurricane Dennis landfall
2. CIO Leadership Series: Greg Smith, Wheaton Franciscan Healthcare
3. GenTel acquires GlaxoSmithKline chip platform
4. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
5. VanderSanden appointed president of AT&T Wisconsin
6. Chemical-petroleum executive joins Virent Energy board
7. Visions: Matheys says CIO role is good training for executive suite
8. Biotech executive books a career flight thats closer to home
9. CEOs Gone Wild? Risks and rewards in the executive suite
10. Early-stage executives hear from investors
11. Pedlar the latest executive to leave Merge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/15/2017)... Charlotte, NC (PRWEB) , ... August 15, 2017 , ... ... in 2017, celebrating 10 years of successes helping medical technology companies and inventors develop ... company to a renowned full-service national engineering firm with a portfolio of clients in ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):